Johnson & Johnson Profile Avatar - Palmy Investing

Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby br…
Drug Manufacturers - General
US, New Brunswick [HQ]

FA

Fundamental Analysis · Most Recent Quarter

It is important to understand the FA Algorithm and the criterias before valuing it as a top-tier resource.

Read Rationale
Framework:
Valuation 14% Weak
Profitability n.A. n.A.
Fin. Growth 33% Weak
Leverage & Liquidity 0% Bad
Per Share Metrics 33% Weak
Fin. Health n.A. n.A.
Fundamentals

Valuation

Metric Q4 Q1 Δ in %
EV/EBITDA -22.39 50.29 64.80
Graham Fair Price -9.57 29.74 32.88
PEG 97.27 < 0.005 -0.23
Price/Book -1.09 5.43 5.49
Price/Cash Flow 121.69 133.32 60.14
Prices/Earnings 25.27 29.18 23.30
Price/Sales 0.75 17.77 17.64
Price/FCF 121.69 133.32 60.14
Naive Interpretation member
01 - Valuation · Weak
Fundamentals

Profitability

Metric Q4 Q1 Δ in %
Gross Profit Margin 2.20 0.69 0.67
Operating Margin 43.62 0.28 0.19
ROA -21.67 0.02 0.02
ROE 0.06 0.05 -21.04
ROIC 0.04 0.05 39.08
Naive Interpretation member
02 - Profitability · Not Interpreted
Fundamentals

Financial Growth

Metric Q4 Q1 Δ in %
Debt QOQ 0.11 0.02 515.71
Dividends QOQ < 0.005 < 0.005 -53.29
EBIT QOQ -0.31 0.44 38.47
EPS QOQ -1.00 46.00 4487.27
FCF QOQ -0.04 -0.55 -1335.22
Revenue QOQ < 0.005 < 0.005 -80.48
Naive Interpretation member
03 - Financial Growth · Weak
Fundamentals

Leverage & Liquidity

Metric Q4 Q1 Δ in %
Assets Turnover n.A. n.A. n.A.
Days Inventory Outstanding (DIO) 143.84 153.46 6.69
Days Sales Outstanding (DSO) 62.58 62.91 0.53
Inventory Turnover 0.63 0.59 -6.27
Debt/Capitalization 0.30 0.32 8.52
Quick Ratio 0.82 0.84 3.44
Naive Interpretation member
04 - Leverage & Liquidity · Bad
Fundamentals

Per Share Metrics

Metric Q4 Q1 Δ in %
Book Value 28.57 29.08 1.77
Cash 9.52 10.89 14.31
Capex -0.66 -0.34 49.23
Free Cash Flow 2.61 1.18 -54.59
Revenue 8.89 8.88 -0.08
Naive Interpretation member
05 - Per Share Metrics · Weak
Fundamentals

Financial Health

Metric Q4 Q1 Δ in %
Current Ratio 1.16 1.17 1.21
Debt/Assets n.A. n.A. n.A.
Debt/Equity n.A. n.A. n.A.
Net Debt/EBITDA 1.44 1.06 -26.57
Naive Interpretation Member
06 - Financial Health · Bad
End of JNJ's Analysis
CIK: 200406 CUSIP: 478160104 ISIN: US4781601046 LEI: - UEI: -
Secondary Listings